Page last checked 2026-08-16

Australia · peptide status

Are peptides legal in Australia? The answer depends on the product

Peptides are not legal or illegal as one group in Australia. Australian law treats peptide products as medicines. Some products are in the ARTG; the TGA names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as unapproved. An unapproved product still needs a valid access route. State and territory laws can add separate rules for possession and supply.

Source: TGA guidance, checked 2026-08-16

1 · Product

Is this product in the ARTG?

The TGA approves products, not the word peptide.

2 · Route

How is it being accessed?

Supply, doctor access, trials and import are separate routes.

3 · Location

Do local controls also apply?

Local rules can also control possession.

Start with the product

Approved and unapproved are product statuses

TGA advisory · 13 April 2026

The Australian Register of Therapeutic Goods is the main product record. The TGA gives insulin as an approved peptide medicine. It also names five peptides as unapproved examples. The list does not cover every peptide outside the ARTG.

How the TGA separates peptide product status, checked 16 August 2026.
Product status	TGA examples	What that status means
Included in the ARTG	Some peptide medicines, including insulin products	The TGA has approved the specific product for its registered use.
Not included in the ARTG	BPC-157, GHK-Cu, TB-500, retatrutide, CJC-1295	The product is unapproved; a specific access or import pathway still has to apply.

Then check the route

Five routes that should not be collapsed into one

ARTG products use the approved supply route. Other routes include the Special Access Scheme, Authorized Prescriber scheme and clinical trials. Personal import is a separate route for use. It is not a supply route.

Australian access routes for peptide medicines.
Route	How it works	Boundary
ARTG-listed product	The approved product’s ordinary Australian supply route	Approval belongs to the specific product included in the ARTG, not to every product containing a peptide.
Special Access Scheme	A health practitioner supplies an unapproved medicine under the applicable SAS category	The prescriber and sponsor must meet the category’s approval, notice and record rules.
Authorized Prescriber	An authorized prescriber supplies an unapproved medicine to the approved patient group	The scheme is a practitioner pathway; it does not place the product in the ARTG.
Clinical trial	The product is supplied through an Australian clinical trial	Trial access is not ordinary commercial availability.
Personal importation	An individual imports for personal use or an immediate family member	This route is for use, not resale or supply, and every scheme condition must be met.

Personal import

A conditional route, not a blanket permission

Every condition must be met

The Personal Importation Scheme may cover a product outside the ARTG. It is only for you or an immediate family member. A late prescription cannot fix an import that was already held.

1
Hold a valid Australian prescription or written authority at the time of import when the medicine is prescription-only in Australia.
2
Import no more than a 3-month supply in one order.
3
Keep the total imported within a 15-month supply during any 12-month period.
4
Use it only for yourself or an immediate family member; do not sell, supply or give it to another person.
5
Keep the identity, active ingredient, strength and dosage information clear and accurate on the product.
6
Do not import a counterfeit product or a controlled or otherwise prohibited substance under this scheme.

What the label must make clear

The TGA will not release an unmarked or code-only vial. The label must show the active ingredient, strength and dose. Australian Border Force may seize and destroy a shipment that breaks the rules.

What “research use only” changes

It does not change the product’s status. The TGA says the phrase does not permit import or remove the rules for ads and supply.

The possession question

Two legal layers, two different records

The TGA sets out the national medicine rules. It also says State and territory laws may add controls on sale, supply and possession. That is why there is no single national answer for possession.

Which Australian record answers which peptide-law question.
Legal layer	What it can decide	Where to check
Australian medicines law	ARTG status, lawful access pathways, personal import conditions and advertising controls	TGA records
State and territory law	Additional controls on sale, supply, possession, storage and scheduled medicines	The medicines and poisons regulator for the relevant state or territory

Public promotion

A clinic ad can also promote a product

Boundary 1

Prescription-only and most pharmacist-only medicines cannot be advertised to the public unless an Australian government authority authorizes or requires it.

Boundary 2

Some products not included in the ARTG cannot lawfully be advertised to the public.

Boundary 3

An ad for a health service can also be regulated when it directly or indirectly advertises a medicine.

Boundary 4

A “research use only” disclaimer does not change a product’s status or remove import, advertising or supply rules.

Questions people actually ask

How to get peptides in Australia?

Start with the exact product. An ARTG-listed product uses its approved supply route. Other routes include the Special Access Scheme, an Authorized Prescriber, a clinical trial or personal import. Each route has its own rules. None gives general permission to buy or supply any peptide.

Is it illegal to possess peptides?

There is no national yes-or-no answer for every peptide. The product and its access route both matter. State and territory laws may also control possession, sale and supply. Check the exact substance and location.

Which peptides can be prescribed in Australia?

A prescription depends on the product and route. Some peptide medicines are in the ARTG. Doctors may use the Special Access Scheme or Authorized Prescriber scheme for some other products. The scheme rules must be met. Unapproved does not mean routinely prescribed.

What peptides can be legally prescribed?

The ARTG is the product approval record. A product outside it still needs a valid access route. In April 2026, the TGA named BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as unapproved examples. It did not call them ordinary approved prescriptions.

What remains uncertain

It does not put every peptide into one legal group.
An access route does not promise that a doctor will prescribe or supply a product.
Personal import does not permit resale or the import of a controlled or counterfeit product.
State and territory records still control local possession rules.

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer

Reviewed 2026-08-16

The TGA names these five examples together. Each compound still has its own evidence record. Product status and human evidence answer different questions.

Continue through the page

The retatrutide routes, and who each shuts out

No published retatrutide price exists at all, because no approved product does.

The 2026/27 NHS England Mounjaro rollout

The confidential NHS price, NICE list price and a private patient’s bill are published as three different things.

The two-year NHS Wegovy boundary

NICE limits NHS treatment to 2 years and separately says to consider stopping after an insufficient 6-month response.

Why Canadian residents cannot generally import prescription peptides

Canadian residents are generally not permitted to personally import prescription drugs.

How every row is checked

The source definitions, citation rules and automated checks used before a figure is published.

Sources

Responsibilities when importing, compounding and supplying unapproved peptide products · Therapeutic Goods Administration · retrieved 2026-08-16
TGA warning on the risks of importing unapproved peptide products · Therapeutic Goods Administration · retrieved 2026-08-16
Personal Importation Scheme · Therapeutic Goods Administration · retrieved 2026-08-16
Supply an unapproved therapeutic good · Therapeutic Goods Administration · retrieved 2026-08-16